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Background: Systemic vasculitis may cause life threatening complications requiring admission to an intensive care
unit (ICU). The aim of this study was to evaluate outcomes of systemic vasculitis patients admitted to the ICU and
to identify prognosis factors.
Methods: During a ten-year period, records of 31 adult patients with systemic vasculitis admitted to ICUs (median
age: 63 y.o, sex ratio M/F: 21/10, SAPS II: 40) were reviewed including clinical and biological parameters, use of
mechanical ventilation, catecholamine or/and dialysis support. Mortality was assessed and data were analyzed to
identify predictive factors of outcome.
Results: Causes of ICU admissions were active manifestation of vasculitis (n = 19), septic shock (n = 8) and
miscellaneous (n = 4). Sixteen patients (52%) died in ICU. By univariate analysis, mortality was associated with higher
SOFA (p = 0.006) and SAPS II (p = 0.004) scores. The need for a catecholamine support or/and a renal replacement
therapy, and the occurrence of an ARDS significantly worsen the prognosis. By multivariate analysis, only SAPS II
(Odd ratio: 1.16, 95% CI [1.01; 1.33]) and BVAS scores (Odd ratio: 1.16, 95% CI = [1.01; 1.34]) were predictive of
mortality.
Conclusion: The mortality rate of severe vasculitis requiring an admission to ICU was high. High levels of SAPS II
and BVAS scores at admission were predictive of mortality.
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The systemic vasculitides are rare diseases defined by ves-
sel inflammation and classified according to the size of the
vessels implicated (Chapel Hill conference) [1,2]. They
share clinical features including fever, arthralgia, respira-
tory distress, renal dysfunction, and neurologic disorders;
but their course and prognosis are heterogeneous. Though
the use of corticotherapy at 50′s and immunosuppressive
therapy at the 70′s significantly improved the outcome
with an increase in 5-year survival rate from 20% to 75%
[3], they may lead to life-threatening complications requir-
ing admission to Intensive Care Unit (ICU). These severe
complications associated with organ failure are mainly
related to active diseases or to post-immunosuppressive
therapy effects mostly infections [4,5].* Correspondence: k-klouche@chu-montpellier.fr
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reproduction in any medium, provided the orFew studies focusing on outcome and prognosis of pa-
tients with vasculitides admitted to ICU have been pub-
lished. Most of the reports included systemic rheumatic
diseases like connectivitis, rheumatoïd polyarthritis, gra-
nulomatosis, primary and systemic vasculitides [6-13].
High mortality rates (30-50%) were observed in such pa-
tients [8,14]. To the best of our knowledge, only 3 studies,
the largest one including 38 patients, specifically investi-
gated vasculitides ICU outcome [6,7,13]. They reported a
lower in-ICU mortality varying from 11% to 33%. However,
a higher mortality rate may occur in case of pulmonary de-
terminations reaching more than 50% [15]. Prognostic sys-
tems developed to predict outcomes in critical illness
[16,17] were evaluated in such patients as well as the level
of vasculitis disease activity. Results showed that severity
scores, APACHE II and/or SAPS II, seem to be good pre-
dictors of ICU mortality by contrast to the severity of the
underlying vasculitis [6,7].
The significant advances, in the past decade, regarding
diagnostic strategies and therapeutic options for vasculitistd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to the use of a more aggressive specific therapy. Thus,
ICU-mortality rate and accurate prediction of patients’
outcome upon ICU admission need to be reassessed.
We therefore carried out a ten-year analysis of a co-
hort of vasculitis patients admitted to ICU in order to
investigate the epidemiology, clinical features and out-
come of their severe complications, and to identify the
predictive factors of mortality.
Methods
This retrospective study was carried out from 2000 to
2010 at Montpellier and Nîmes University hospitals. All
adult patients with systemic vasculitis admitted to four
Intensive Care Units (ICUs) (3 medical and 1 medico-
surgical ICUs) with a length of stay above 24 hours were
included in the study. They were identified from our
local informatics’ database. Our local institutional Re-
view Board (Comité de Protection des Personnes Sud
Mediterranee IV, Q-2013-09-03) approved the study and
waived the need for informed consent.
Vasculitis was classified according to the Chapel Hill
conference [2] or to the American College of Rhumatology
definitions [18] regarding polyarteritis nodosa, Granulo-
matosis with polyangiitis (Wegener’s granulomatosis) and
Eosinophilic Granulomatosis with polyangiitis (Churg-
Strauss). When a patient was hospitalized twice or more,
the only first ICU admission was considered. Patients with
connective tissue disease (lupus, polyarteritis rheumatoid,
others) or primary focal vasculitis (cerebral vasculitis) were
excluded. Clinical charts were retrospectively reviewed.
Age, sex, and immunosuppressive treatment (above 20 mg
daily corticosteroid or/and Cyclophosphamide or Azia-
thioprine during the 3 months preceding ICU admission)
were collected. None of the included patients received bio-
logics like rituximab or infliximab … Upon ICU admission,
the reasons for admission were noted and the clinical and
biological variables monitored. The severity of the disease
was assessed 24 h after admission using the simplified
acute physiology score (SAPS) II [16] and the sequential
organ failure assessment (SOFA) scores [17] and by the
Birmingham Vasculitis Activity Score (BVAS) [19]. BVAS
is a clinical index of vasculitis activity based on symptoms
and signs in nine separate organ systems (systemic signs;
skin; mucous membranes and eyes; ear; nose and throat;
chest; heart and vessels; gastrointestinal tract; kidney; and
nervous system). Presence of a sepsis [20] and source and
microorganisms when identified, the occurrence of an
acute respiratory distress syndrome (ARDS) [21] or/and a
pneumo-renal syndrome [22] were recorded.
During ICU stay, the need for mechanical ventilation,
or/and dialysis, or/and vasoactive drugs and their duration
use were monitored. ICU length of stay was recorded as
well as outcome at ICU discharge. ICU outcome wascompared to a control group of matched non-vasculitis
ICU patients. The control ICU patients were extracted
from our own database and they were frequency matched
to cases by age, SAPS II and SOFA scores. One year out-
come of ICU survivors was established by phone call or
mail interrogating them or their next of kin.
We divided our patients according to ICU mortality
and compared survivors and nonsurvivors for all the
above variables in order to identify the predictive factors
of outcome.
Statistical analysis
The statistical analyses were performed using STATA
11.0 (StataCorp LP, Texas 77845, USA). We first per-
formed a descriptive analysis by computing the frequen-
cies and the percents for categorial data, median and
range for continuous data. To analyze the factors associ-
ated with the ICU mortality, univariate and multivariate
analyses were performed. The univariate analysis was
performed using two-tailed Mann–Whitney test for
quantitative variables and Pearson’s Chi-2 test or Fisher’s
exact test for qualitative variables when appropriate.
Multivariate analysis was performed by logistic regres-
sion in order to evaluate the adjusted effects of the dif-
ferent variables. We built the final multivariate model
using a backward strategy with all clinical variables mea-
sured before or at the admission in the ICU having a
p-value less than 10% in univariate analysis. At each
step, the variable with the least significant p value was
removed until all remaining main effects in the model
were significant at p < 0.05. A long-term survival curve
was generated using the Kaplan-Meier methodology. A
value of p < 0.05 was considered as significant.
Results
Population and mortality
Thirty-one patients, ten females and twenty-one males,
were included in the study. Patient characteristics are
summarized in Table 1. Vasculitis types included Granu-
lomatosis with polyangiitis (n = 15), polyarteritis nodosa
(n = 4), IgA vasculitis (n = 4), cryoglobulinemia (n = 3),
Giant cell angiitis (n = 2), Eosinophilic Granulomatosis
with polyangiitis (n =1), and microscopic polyangiitis
(n = 2). Twenty-two patients with a previous established
diagnosis of vasculitis received a corticotherapy and 10 of
them received an immunosuppressive treatment (Cyclo-
phosphamide or Aziathioprine) in the previous 3 months.
Vasculitis was diagnosed during ICU stay in 7 cases
(23%): Granulomatosis with polyangiitis n = 5, Eosino-
philic Granulomatosis with polyangiitis n = 1 and micro-
scopic polyangiitis n = 1.
Main reasons for ICU admission were active vasculitis
(19 patients, 61%) including pneumo-renal syndrome
(n = 9), pulmonary haemorrhage (n = 4), cardiogenic shock
Table 1 Patients characteristics
Characteristics
Age, years 63 (29–86)
Male/female, n 21/10





Chronic renal failure 4
Chronic respiratory failure 2
Non Insulin dependent diabetes 4
Creatininemia, μmol/l 232 (32–1067)
SAPS II 40 (13–109)
SOFA 5,5 (1–14)
BVAS 22 (2–52)
ICU length of stay, days 14 (1–113)
In hospital length of stay, days 39 (6–288)
ICU mortality, n (%) 16 (52%)
Data are presented as median (range), otherwise specified.
SAPSII simplified acute physiology score II, SOFA sequential organ failure
assessment, BVAS Birmingham Vasculitis Activity Score, ICU severity scores were
assessed 24 hours after ICU admission.
Table 2 Main therapeutic interventions during ICU stay
Therapeutic intervention
Noninvasive ventilation, n (%) 4 (13%)
Duration, days 4,5 (1–11)
Invasive ventilation, n (%) 25 (81%)
Duration, days 11 (1–109)
Vasopressive drugs, n (%) 14 (45%)
Duration, days 2,5 (2–27)
Inotropic drugs, n (%) 5 (16%)
Duration, days 5 (2–20)
RRT, n (%) 18 (58%)
Duration, days 3,5 (1–66)
Data are presented as median (range), otherwise specified.
RRT renal replacement therapy.







Age, yo 58 ± 12.8 61 ± 13.5 0.78
SAPS II 39.4 ± 16.6 42 ± 21 0.21
SOFA 5.6 ± 3.5 6.2 ± 4.1 0.9
Deceased, n (%) 6 (19.4) 16 (51.6) 0.001
Data are presented as mean ± standard deviation.
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(n = 2), acute renal failure associated with distal arterial is-
chemia during polyarteritis nodosa (n = 1), central neuro-
logic involvement in polyarteritis nodosa (n = 1). Eight
(26%) patients were admitted for septic shock, and four
(13%) for other reasons: subdural hematoma on anticoagu-
lant therapy (n = 1), haemorrhagic shock following hepatic
biopsy (n = 1), severe pulmonary embolism (n = 1), and
severe post-surgery complication (n = 1). As shown in
Table 1, high median SAPS II and SOFA scores underlined
the severity of the patient illnesses. During ICU stay, spe-
cific vasculitis treatment included corticosteroids in 28 pa-
tients, Cyclophosphamide in 12, plasma exchange in 6 and
intravenous immunoglobulins in 6 patients. Any patient
may received one or more specific treatment. Twenty-five
patients (81%) were on mechanical ventilation, 18 (58%)
underwent hemodialysis, and 14 (45%) required a catechol-
amine support. ICU therapeutic management is displayed
in Table 2. Nosocomial or secondary infections occurred
frequently: 8 ventilator associated pneumonia (Escherichia
coli 1, Enterobacter aerogenes 1, Enterobacter cloacae 1,
Xanthomonas maltophilia 1, Pseudomonas aeruginosa 1,
Staphylococcus aureus 1, Mycobacterium xenopi 1, Strep-
tococcus pneumoniae 1), 5 bacteraemia (Staphylococcus
aureus 3, Corynebacterium jekium 1, Anaerobia 1), 5 viral
cytomegalovirus infections (pneumonia 2, colitis 1, oeso-
phagitis 1, cutaneous ulceration 1), and 2 mycotic in-
fections (Parapsilosis candidemia 1, Aspergillus fumigatuspneumoniae 1). Median ICU length of stay was 14 (1;113)
days.
Sixteen patients (52%) died in ICU. This ICU mortality
was significantly higher than that of the control group of
ICU patients which was at 20%; differences between these
two groups are displayed in Table 3. Reasons of death were
septic shock (n = 7), refractory hypoxemia during ARDS
(n = 7: infectious 3 and intraalveolar haemorrhage 4), ven-
tricular fibrillation during myocardial infarction (n = 1)
and fatal subarachnoidal haemorrhage (n = 1). Causes of
death according to the vasculitis diagnosis are displayed in
Table 4. Two patients died during the one-year follow-up
which brings mortality to 58%. Figure 1 represents the
Kaplan-Meier curve for one year-survival after admission
to the ICU.
Prognostic analysis of the 31 vasculitis patients admitted
to the ICU
By univariate analysis, the comparison between survivors
and non-survivors showed that ICU mortality was statis-
tically associated with higher age (p = 0.04), SOFA (p =
0.006) and SAPS II (p = 0.004) scores (Table 5). There
was a tendency that deceased patients had higher BVAS
scores compared to survivors (p = 0.06). No differences
in comorbities and prior health status were observed be-
tween surviving and non-surviving patients. During ICU
Table 4 Causes of death according to vasculitis diagnosis
Deceased Causes of death n
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ment therapy was also associated with ICU mortality.
The occurrence of an ARDS worsened significantly the
prognosis. ICU length of stay was similar between the
two groups.
Among the variables from the univariate analysis in-
cluded in the multivariate model, SAPS II and BVAS
scores (at any given number) were independently related
to the mortality. The adjusted odds ratio for the ICU
mortality associated with BVAS and SAPS II were 1.16
(95% CI = [1.01- 1.34]) and 1.16 (95% CI = [1.01-1.33])
respectively. No other variable associated with mortality
in the univariate analysis remained significant in the








Age, years 69,5 [29–86] 57 [32–78] 0,04Discussion
The aim of the current study was to describe the epi-
demiology, the clinical features, and the outcome of
vasculitis patients who were admitted to an ICU. The
mortality rate for this population was 52% in the ICU
and 58% one year later which was significantly higher
than the mortality rate for a general ICU population
(less than 20% in our ICU). Our results demonstrate also
that SAPS II and BVAS scores were the main indepen-




Figure 1 Kaplan-Meier curve for one year survival after ICU
admission of patients with vasculitis diseases. The number of
patients at different time points is displayed under the curve.Systemic necrotizing vasculitis is a group of diseases de-
fined by vessel wall inflammation that, although heteroge-
neous, shares some common clinical characteristics and
therapeutic management. ICU admissions of such patients
are mainly justified by the occurrence of severe active
disease related-organ dysfunction or severe complication
of immunosuppressive therapy, mostly infection. In this
study, severe active manifestation of the disease was
the reason of ICU admission in 61% of our patients. A
pneumo-renal syndrome with both acute pulmonary and
renal failure occurred in 9 patients and, as a manifestation
of Granulomatosis with polyangiitis in 8 of them. Cruz
and colleagues [6], including 26 patients with systemic
necrotizing vasculitis, found also an active manifestation
(77%) as a major reason of ICU. It is noteworthy in their
report that vasculitis exacerbation was often the first
manifestation of the disease leading to its diagnosis which
was the case in 7 (23%) of our patients. In the study of
Khan et al. [7], diffuse alveolar hemorrhage was the most
frequent reason of ICU admission which is also an activeSex ratio, m/f 12/4 9/6 0,45
BVAS 24.5 [12.0-52.0] 21.0 [2.0-28.0 ] 0,06
SAPS II 46.5 [21.0-109.0] 35.0 [13.0- 51.0] 0,004
Mechanical Ventilation, n (%) 15 (94%) 10 (67%) 0.08
SOFA 7.0 [2.0-15.0] 3.5 [1.0-10.0] 0.006
VAP, n (%) 10 (62.5%) 10 (66.7%) 0.80
Vasopressive agents, n (%) 13 (81,3%) 5 (33,3%) 0.006
ARDS, n (%) 13 (81,3%) 4 (26,7%) 0.002
RRT, n (%) 13 (81,3%) 5 (33,3%) 0.007
Creatininemia, microm/l 297 [56–1067.0] 76 [32–449] 0.062
Data are presented as median (range) or No/total patients.
BVAS Birmingham Vasculitis Activity Score, SAPSII simplified acute physiology
score II, SOFA sequential organ failure assessment, VAP ventilator associated
pneumonia, ARDS acute respiratory distress syndrome, RRT renal replacement
therapy.
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lar haemorrhage was reported as the first disease manifest-
ation in 46 (86.8%) of 53 patients with ANCA-associated
vasculitis [23]. Infections represent the second cause of
ICU admission [7] as in ours. Eight (26%) patients pre-
sented indeed a septic shock requiring critical care man-
agement. The well recognized risk of infection in these
patients is increased [4]; and is determined primarily by
the level of immunosuppression. Actually, all the 8 pa-
tients admitted for severe sepsis received more than
20 mg steroids daily at least in the last three months.
Godeau et al. [8] showed, in a study including 181 patients
with systemic rheumatic disease admitted to ICU that, in
the sub-group of 39 vasculitis, the admission infection rate
was at 49%. However, the immunosuppressive treatment
was not reported precisely.
ICU severity scores and critical care management of our
population underlined its high morbidity. More than ¾ of
patients were on mechanical ventilation, more than half
required vasopressive or inotropic drugs and renal re-
placement therapy. For comparison, Khan [7] found that
45% of patients were ventilated and 29% underwent
hemodialysis. The ICU mortality in our cohort was 52%
which is higher than that of a general ICU population [9].
This high ICU mortality rate underscores the pejorative
role of the specific disease and/or of long term immuno-
suppressive treatment. Studies focusing on outcome and
prognosis of patients with vasculitis admitted to ICU are
scarce. They include mostly systemic rheumatic diseases
like connectivitis, rheumatoïd polyarthritis, granuloma-
tosis, primary vasculitis and systemic vasculitis [10-12]. To
the best of our knowledge, only 3 studies investigated spe-
cifically vasculitis ICU outcome and reported lower mor-
tality rates varying from 11 to 33,3% [6,7,13]. However,
these results should be interpreted with caution, at least
under the light of the severity of both the specific disease
and the associated organ failure. As earlier notified, 80% of
our patients were mechanically ventilated with severe re-
spiratory disease and patients with pulmonary vasculitis
were reported to have an ICU mortality of more than 50%
depending on the disease severity [15,24,25]. Last, we ob-
served that two patients among survivors deceased one
year after they were discharged from hospital underlying
that the occurrence of severe complications requiring an
ICU admission may also affect long term survival [15].
Previous studies reported similarly a significant increase
in mortality at a one year (from 11 to 29%) [7], and a
30 months (from 15 to 39%) [6] follow-up. In the recent
report of Hruskova and colleagues [23], the long-term
prognosis of patients with severe ANCA-associated vascu-
litis showed that the mortality increased from 17% at
3 months to 41.5% at 49 months median follow-up.
The identification of predictive factors for ICU mortality
in such patients is obviously an important matter to study,since it may help in an optimal follow-up and manage-
ment. Several factors have been previously reported to be
predictive of ICU mortality [16,17]. We identified SOFA
and SAPS II severity scores, the need for catecholamine
or/and renal replacement therapy and the occurrence of
an ARDS as prognosis factors by univariate analysis. How-
ever including these parameters in a multivariate analysis,
only SAPS II and BVAS scores were associated with an in-
creased risk of ICU mortality. ICU gravity scores especially
SAPS II and SOFA scores were previously reported as pre-
dictive factors of mortality for vasculitis in ICU in several
studies [6,7,13]. By contrast, BVAS score was not found to
be correlated to ICU mortality [6,7,13]. Cruz and col-
leagues [6] observed similar BVAS scores in survivors and
non survivors (16,4±10.3 vs 15.8±20.1; p = 0.75) in a 30-
month follow-up. Khan et al. [7], using a modified BVAS/
WG score adapted to Granulomatosis with polyangiitis,
also failed to correlate it with a 28 day ICU mortality.
Frausova and al. [13] reported even a higher, although not
significant, BVAS in survivors (16.1 vs 11.5). Our observa-
tion need to be confirmed but highly suggests that vascu-
litis disease activity influence short-term prognosis. Cruz
et al. [6] found however that BVAS calculated at ICU
admission was significantly higher in non-survivors than
survivors at the end of a long-term follow-up of patients
with active systemic necrotising vasculitis.
We must acknowledge some limitations to our study.
First, it was limited to 4 ICUs from 2 university hospitals
and consequently its findings should not be generalized.
The sample size is, in addition, relatively small and het-
erogeneous given the rarity of these diseases. Second, it
is a retrospective study which may therefore be affected
by various biases. Third, immunosuppressive treatments
had changed between individuals which may represent
additional bias in the interpretation of the results.Conclusion
In summary, severe vasculitis complications requiring
admission to the ICU are mostly of active disease mani-
festation or infectious origin. ICU mortality is signifi-
cantly higher underlying the role of intensive or long
term immunosuppression on worsening the outcome.
SAPS II and BVAS scores upon ICU admission are pre-
dictive factors of mortality and may be helpful to early
identify high risk patients.Consent
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